Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy and safety of Maraviroc in prevention of acute GVHD in patients undergoing non-myeloablative allogeneic SCT.
David Porter, MD
University of Pennsylvania
United States: Food and Drug Administration
|University of Pennsylvania Abramson Cancer Center||Philadelphia, Pennsylvania 19104|